506 related articles for article (PubMed ID: 15057291)
1. The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Bartlett JB; Dredge K; Dalgleish AG
Nat Rev Cancer; 2004 Apr; 4(4):314-22. PubMed ID: 15057291
[No Abstract] [Full Text] [Related]
2. Properties of thalidomide and its analogues: implications for anticancer therapy.
Teo SK
AAPS J; 2005 Mar; 7(1):E14-9. PubMed ID: 16146335
[TBL] [Abstract][Full Text] [Related]
3. Recent studies on the thalidomide and its derivatives.
Łączkowski KZ; Baranowska-Łączkowska A
Future Med Chem; 2018 Sep; 10(18):2133-2136. PubMed ID: 30088422
[No Abstract] [Full Text] [Related]
4. [Thalidomide--new prospective therapy in oncology].
Pałgan K; Pałgan I
Wiad Lek; 2003; 56(9-10):455-9. PubMed ID: 15049211
[TBL] [Abstract][Full Text] [Related]
5. The thalidomide saga.
Melchert M; List A
Int J Biochem Cell Biol; 2007; 39(7-8):1489-99. PubMed ID: 17369076
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma.
D'Amato RJ; Lentzsch S; Anderson KC; Rogers MS
Semin Oncol; 2001 Dec; 28(6):597-601. PubMed ID: 11740816
[TBL] [Abstract][Full Text] [Related]
7. Thalidomide in the treatment of cancer.
Adlard JW
Anticancer Drugs; 2000 Nov; 11(10):787-91. PubMed ID: 11142686
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide - current understanding of mechanistic properties.
Tageja N
Anticancer Agents Med Chem; 2011 Mar; 11(3):315-26. PubMed ID: 21426296
[TBL] [Abstract][Full Text] [Related]
9. Thalidomide analogs as emerging anti-cancer drugs.
Dredge K; Dalgleish AG; Marriott JB
Anticancer Drugs; 2003 Jun; 14(5):331-5. PubMed ID: 12782937
[TBL] [Abstract][Full Text] [Related]
10. The use of thalidomide in myeloma therapy as an effective anticancer drug.
Sze DM; Brown R; Yang S; Ho PJ; Gibson J; Joshua D
Curr Cancer Drug Targets; 2006 Jun; 6(4):325-31. PubMed ID: 16848723
[TBL] [Abstract][Full Text] [Related]
11. Current status of thalidomide in the treatment of cancer.
Rajkumar SV
Oncology (Williston Park); 2001 Jul; 15(7):867-74; discussion 877-9. PubMed ID: 11499688
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulatory properties of thalidomide analogs: pomalidomide and lenalidomide, experimental and therapeutic applications.
Bodera P; Stankiewicz W
Recent Pat Endocr Metab Immune Drug Discov; 2011 Sep; 5(3):192-6. PubMed ID: 21913886
[TBL] [Abstract][Full Text] [Related]
13. Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma.
Mark TM; Coleman M; Niesvizky R
Leuk Res; 2014 May; 38(5):517-24. PubMed ID: 24690110
[TBL] [Abstract][Full Text] [Related]
14. [New indications for thalidomide?].
Tuinmann G; Hegewisch-Becker S; Hossfeld DK
Dtsch Med Wochenschr; 2001 Oct; 126(42):1178-82. PubMed ID: 11607859
[No Abstract] [Full Text] [Related]
15. Thalidomide in cancer medicine.
Eleutherakis-Papaiakovou V; Bamias A; Dimopoulos MA
Ann Oncol; 2004 Aug; 15(8):1151-60. PubMed ID: 15277253
[TBL] [Abstract][Full Text] [Related]
16. Thalidomide derived immunomodulatory drugs (IMiDs) as potential therapeutic agents.
Marriott JB; Dredge K; Dalgleish AG
Curr Drug Targets Immune Endocr Metabol Disord; 2003 Sep; 3(3):181-6. PubMed ID: 12871024
[TBL] [Abstract][Full Text] [Related]
17. Thalidomide: present and future in multiple myeloma.
Hussein MA
Expert Rev Anticancer Ther; 2005 Feb; 5(1):25-31. PubMed ID: 15757435
[TBL] [Abstract][Full Text] [Related]
18. Pomalidomide: when expectations are understated.
Di Raimondo F; Conticello C
Future Oncol; 2017 Feb; 13(5s):1-2. PubMed ID: 28116940
[No Abstract] [Full Text] [Related]
19. Thalidomide and lenalidomide in the treatment of multiple myeloma.
Kumar S; Rajkumar SV
Eur J Cancer; 2006 Jul; 42(11):1612-22. PubMed ID: 16750621
[TBL] [Abstract][Full Text] [Related]
20. Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy.
Shortt J; Hsu AK; Johnstone RW
Oncogene; 2013 Sep; 32(36):4191-202. PubMed ID: 23318436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
